Business Context and Reporting Period
Company: Omeros Corporation (OMER)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Omeros is a commercial-stage biotechnology company focused on complement-mediated diseases, cancers, and addictive disorders. Its primary commercial product, YARTEMLEA (narsoplimab-wuug), received FDA approval in December 2025 for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Commercial sales commenced in January 2026. The company also retains rights to its MASP-3 small-molecule program and other pipeline assets following the sale of zaltenibart to Novo Nordisk in late 2025.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Product Sales, Net | $28.5 million | $38.4 million |
| Net Income (Loss) | $13.2 million | $69.3 million |
| Net Income from Continuing Operations | $6.6 million | $57.9 million |
| Net Income from Discontinued Operations | $6.6 million | $11.4 million |
| Operating Income (Loss) | $0.1 million | $(17.3) million |
| Cash and Cash Equivalents | $2.0 million | $2.0 million (Ending Balance) |
| Short-Term Investments | $130.0 million | $130.0 million (Ending Balance) |
| Total Liquidity (Cash + ST Investments) | $132.0 million | $132.0 million |
| Debt (2029 Notes Principal) | $54.8 million (Outstanding) | $54.8 million (Outstanding) |
| OMIDRIA Royalty Obligation | $157.9 million | $157.9 million |
Note: Net income for the period was significantly influenced by a non-cash gain of $84.6 million on the change in fair value of financial instruments (embedded derivatives on debt) and income from discontinued operations related to the OMIDRIA royalty asset.
Material Changes vs. Prior Period
- Revenue Generation: The company transitioned from zero product sales in the prior year to $28.5 million in net product sales for the quarter ended June 30, 2026, driven by the commercial launch of YARTEMLEA.
- Profitability: The company reported a net income of $13.2 million for the quarter, compared to a net loss of $25.4 million in the same period in 2025. This reversal was primarily due to the non-cash gain on embedded derivatives ($11.4 million) and income from discontinued operations ($6.6 million), offsetting operating losses.
- Debt Restructuring: The company repaid its 2026 Notes in full in February 2026. Additionally, in June and July 2026, the company entered into agreements to repurchase approximately $30.5 million in aggregate principal of its 2029 Notes, reducing the outstanding principal to approximately $40.3 million.
- Expense Reduction: Research and development expenses decreased by $8.2 million for the quarter compared to the prior year, largely due to the sale of the zaltenibart program to Novo Nordisk.
- Share Repurchases: The company repurchased and retired approximately 0.5 million shares of common stock during the quarter at an average price of $11.70 per share.
Guidance, Outlook, and Risks
- Commercial Outlook: Management expects selling, general, and administrative (SG&A) expenses to increase in the third quarter of 2026 due to continued build-out of the commercial organization for YARTEMLEA. R&D expenses are also expected to rise due to investments in YARTEMLEA expansion and the OncotoX-AML program.
- Regulatory Status: In June 2026, the European Medicines Agency (EMA) adopted a negative opinion on the marketing authorization application for YARTEMLEA in TA-TMA. Omeros has requested a re-examination by an Ad Hoc Expert Group. Approval is not guaranteed.
- Liquidity: The company expects to fund more than 12 months of operations using current cash, cash equivalents, short-term investments, and anticipated commercial sales of YARTEMLEA.
- Key Risks:
- Derivative Volatility: The company's reported earnings are heavily influenced by the fair value remeasurement of embedded derivatives on its 2029 Notes. A 20% swing in stock price could result in an approximate $15.8 million change in the derivative's fair value.
- Regulatory Uncertainty: Failure to secure EMA approval or delays in expanding the YARTEMLEA label could impact future revenue projections.
- Debt Obligations: Significant obligations remain, including the OMIDRIA royalty obligation ($157.9 million) and the 2029 Notes.
Investor Verification Checklist
- Derivative Impact: Verify the extent to which reported net income is driven by non-cash fair value adjustments on the 2029 Notes embedded derivative versus core operating performance.
- YARTEMLEA Adoption: Monitor the number of unique ordering accounts and gross-to-net revenue adjustments to assess the sustainability of commercial growth.
- EMA Re-examination: Track the status of the EMA re-examination process for YARTEMLEA, as a negative final decision would limit international expansion.
- Debt Repurchase Terms: Confirm the final settlement terms and accounting impact of the second tranche of 2029 Notes repurchases completed in July 2026.
- OMIDRIA Royalty Forecast: Review assumptions used to value the OMIDRIA contract royalty asset and obligation, as remeasurements significantly impact discontinued operations income.